Your session is about to expire
← Back to Search
PT-112 Injection for Advanced Prostate Cancer
Study Summary
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- More than 25% of my bone marrow has been exposed to radiation.I have not had major surgery in the last 28 days.My prostate cancer was confirmed by a lab test.My organ functions are within normal ranges.I am a man aged 18 or older.My prostate cancer has spread and is resistant to hormone therapy.I haven't taken any immune-modifying, cancer hormone treatments, steroids, or growth factors in the last 14 days.I have not had radiotherapy in the last 14 days.I haven't had chemotherapy in the last 21 days.I have undergone three or more treatments for my advanced cancer.I am fully active or can carry out light work.My cancer is growing, as shown by tests or markers.My brain metastases are stable, whether treated or not.My bone marrow is not healthy enough for this trial.
- Group 1: Arm 2: PT-112 injection
- Group 2: Arm 1: PT-112 injection
- Group 3: Arm 3: PT-112 injection
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there ample locations conducting this clinical experiment in the state?
"Various locations are partaking in the recruitment of patients, such as Indianapolis, Albuquerque and Durham. In total 12 different sites have opened their enrollment to this study."
What is the target outcome of this experimental investigation?
"This 28-day clinical trial seeks to determine the optimal dose and schedule for PT-112 in preparation for pivotal studies. Specific secondary objectives include achieving an objective response rate (ORR) with RECIST-measurable diseases, attaining CTC0 from nonzero baseline measurements, and observing any anti-tumor effects through physical examinations or imaging techniques every two cycles."
Has PT-112 Injection been given FDA authorization?
"With prior evidence suggesting its safety, PT-112 Injection was rated a 2 on the 1 to 3 scale. However, there is no available data confirming efficacy of this drug yet."
Is recruitment for this experiment still ongoing?
"Data posted on clinicaltrials.gov confirms that the trial is actively recruiting subjects; it was first published on July 1st 2014 and last edited November 14th 2022."
What is the upper limit of participants taking part in this medical experiment?
"This medical research necessitates the participation of 180 eligible individuals. Those who qualify can join from two sites, one in Indianapolis, Indiana and another in Albuquerque, New mexico."
Share this study with friends
Copy Link
Messenger